Perspective Therapeutics shares are trading higher after the company announced the first meningioma patient dosed with VMT-α-NET in the ongoing Phase 1/2a study.

Benzinga Newsdesk www.benzinga.com Positive 95.3%

Neg 0% Neu 0% Pos 95.3%

Comments

No comments yet. Be the first!